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ABSTRACT
Objective: Extensively drug-resistant tuberculosis (XDR-TB) strains were emerged when multidrug-resistant TB (MDR-
TB) was inadequately treated. Inadequate treatment of MDR-TB cases may result in additional resistance especially 
non-XDR-TB and then XDR-TB. The aim of this study was to know the prevalence, resistance patterns and trends of the 
XDR-TB strains among the MDR-TB at a tertiary care hospital in Lucknow, India
Methods: A total of 430 Mycobacterium isolates were underwent NAP test and TB MPT64 Ag test for the identification 
of Mycobacterium tuberculosis complex (MTBC). Drug-susceptibility test (DST) was performed over MTBC for the first 
line drugs by 1% proportion method (Bactec) and for the second-line drugs by 1% proportion method (Lowenstein-
Jensen media). The XDR-TB status was further confirmed by line probe assay (GenoType® MTBDRsl assay).
Results: Among the 430 isolates of mycobacterium, 365 (84.9%) were MTBC and 139 (38.1%) were MDR-TB respectively. 
Further 97 MDR-TB from “highly suspected drug resistant-TB (DR-TB)” cases among MDR-TB were tested with second 
line drugs in which 15 (15.5%) XDR-TB and 82 (84.5%) were non-XDR-TB. Regarding XDR-TB status, using the 1% 
proportion method a 100% agreement was seen with the GenoType® MTBDRsl assay. Resistance patterns of XDR-TB 
were as; 10/15 (66.7%) as isoniazid + rifampicin + ciprofloxacin + amikacin resistance and 5/15 (33.3%) as isoniazid + 
rifampicin + ciprofloxacin + amikacin + kanamycin resistance.
Conclusion: The prevalence of XDR-TB was 15.5% among MDR-TB. Hence laboratory testing of “highly suspected drug 
resistant-TB” isolates should be done for both first and second line drugs simultaneously especially in developing coun-
tries. J Microbiol Infect Dis 2013;3(4): 169-175
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Genişlemiş ilaca dirençli tüberküloz paterni ve trendi: 5 yıllık deneyim
ÖZET
Amaç: Genişlemiş drug-rezistan tüberküloz (XDR-TB) suşları multi-drug rezistan tüberküloz (MDR-TB) suşlarının uygun-
suz tedavisiyle önem kazandı. Multi-drug rezistan tüberküloz (MDR-TB) suşları ile infekte olguların uygunsuz tedavisi 
özellikle XDR-TB dışı ve XDR-TB’a yol açabilir. Bu çalışmada Hindistan’ın Luckdown şehrindeki bir üçüncü basamak 
hastanesinde multidrug-rezistan tüberküloz suşları arasında genişlemiş drug-rezistans paterni ve trendinin araştırılması 
amaçlandı. 
Yöntemler: Çalışmada Mycobacteruim tuberculosis complex (MTBC) identifikasyonu için 430 mikobakteri suşu NAP testi 
ve TB MPT64 Ag testine tabi tutuldu. İlaç duyarlılıklarının belirlenmesinde ilk sıra ilaçlar için % 1 proporsiyon metodu 
(Bactec) XDR-TB durumu GenoType® MTBDRslassay ile doğrulandı.
Bulgular: Toplam 430 mikobakteriden 365’i (% 84,9) MTBC ve 139’u (% 38,1) MDR-TB olarak tanımlandı. Yüksek oranda 
drug-rezistan-TB (DR-TB) olarak düşünülen 97 MDR-TB suşu ikinci sıra antitüberküloz ilaçlara duyarlılık açısındn test 
edildiğinde suşlardan 15’i (% 15,5) XDR-TB ve 82’si (% 84,5) ise XDR-TB dışı suşlar idi. XDR-TB suşlarının tamamı %1 
proporsiyon testi kullanılarak GenoType® MTBDRsl assay ile doğrulandı. Toplam 15 XDR-TB suşundan 10’u (% 66,7) 
izoniazid + rifampisin + siprofloksazin + amikasin ve 5’i (% 33,3%) izoniazid + rifampisin + siprofloksazin + amikasin + 
kanamisin’e dirençli olarak değerlendirildi.
Sonuç: Bu çalışmada MDR-TB suşları arasında XDR-TB prevalansı % 15,5 olarak bulunmuştur. Bu yüzden özellikle ge-
lişmekte olan ülkelerde yüksek şüpheli drug-rezistan TB durumunda suşların ilk ve ikinci sıra antitüberküloz ilaçlara 
duyarlılığının birlikte araştırılması gerektiğini düşünüyoruz. 
Anahtar kelimeler: Mycobacterium tuberculosis, genişlemiş drug-rezistan tüberküloz, multidrug-rezistan tüberküloz, 
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INTRODUCTION
A significant high morbidity and mortality due to tu-
berculosis (TB) is reported from India contributing 
one-fifth of the global burden and two persons are 
die in every three minutes in this country, thus nearly 
1000 person a day.1-2 An estimated 2 billion people 
worldwide are infected with Mycobacterium tuber-
culosis, which remains a vast reservoir of potential 
tuberculosis cases. TB is the major co-infection in 
HIV infected patients.3 At present, about 5% of new 
tuberculosis cases in India occur in people infected 
with HIV infection. An extremely worrisome aspect 
of M. tuberculosis is a recent rise to multi drug-re-
sistant (MDR) and extremely drug-resistant (XDR) 
TB.4 However load of MDR-TB accounting for al-
most 50% of world total cases carry together by In-
dia and China alone.2 Due to their drug resistance, 
M. tuberculosis have emerged as a serious problem 
in the world. MDR-TB (defined as in vitro resistance 
to anti-tuberculous drugs, isoniazid and rifampicin) 
and XDR-TB (defined as in vitro resistance to iso-
niazid, rifampicin, any fluoroquinolones and at least 
one of three injectable second-line drugs) are now 
widely reported.4-7
According to World Health Organization (WHO) 
2011 tuberculous report, number of XDR-TB propor-
tionally depend upon number of increased MDR-TB 
cases, since the 69 countries have reported XDR-
TB cases and estimated that 25.000 cases emerg-
ing every year as confirmed XDR-TB cases.8 This is 
the first study from Northern India showing different 
patterns and trends of XDR-TB and lack of proper 
anti-tubercular therapy leading to development of 
further drug resistance like non-XDR-TB and then 
XDR-TB. Therefore the aim of this study is to know 
laboratory  based prevalence  and drug resistance 
patterns of XDR-TB strains among MDR-TB at a 
tertiary care referral centre in Lucknow, India.
METHODS
Isolation and identification of Mycobacterium
Between January 2007 and December 2011, a total 
of 430 consecutive culture positive isolates (Bactec 
12B, Becton Dickinson, USA) were included at a 
tertiary care hospital in Lucknow. This study was 
conducted  after  approval  by  the  local  research 
ethics committee. Informed consent was obtained 
from the patients for sample collection and enroll-
ment in this study. The entire patient’s related in-
formation was taken from the hospital information 
system (HIS) to know whether the patient was new 
or previously treated with anti-tubercular treatment 
(ATT),  duration  of  ATT,  HIV  status,  whether  the 
patient was on anti-retroviral therapy (ART), age, 
sex, types of TB (pulmonary or extra-pulmonary). 
Culture positive Mycobacterium tuberculosis com-
plex (MTBC) strains isolated in Bactec 12B bottles 
were sub-cultured on Lowenstein-Jensen medium 
for enrichment. The isolates were re-suspended by 
pipetting 0.5 ml of 7H9 broth to the slope, and then 
the  suspension  was  transferred  to  cryovials  and 
kept at −70°C until required for further testing.8 All 
isolates were tested with (p-nitro-α-acetylamino-β-
hydroxy propiophenone) NAP test 9 (Becton Dickin-
son, Sparks, MD, USA) and further validated by TB 
Ag MPT64 rapid test (SD Standard Diagnostics, Inc. 
Yongin-si, Korea) for identification of MTBC were in-
cluded for this study.10-11
Drug-susceptibility testing for first line drugs
Drug resistance patterns of all MTBC isolates for 
first line anti-TB drug susceptibility test (DST) were 
done by 1% proportion method using Bactec 460 
12B medium (Becton Dickinson, Sparks, MD, USA). 
The first line drugs were provided in a drug kit (Bec-
ton Dickinson, Sparks, MD, USA). Following final 
drug  concentrations  were  used;  isoniazid  (H)-0.1 
mcg/mL,  rifampicin  (R)-2.0  mcg/mL,  streptomycin 
(S)-6.0 mcg/mL and ethambutol (E)-7.5 mcg/mL. 
Drug-susceptibility testing for second line drugs
Further,  97  isolates  out  of  139  MDR-TB  strains, 
from those subjects who were already on second 
line ATT for more than two months or planned for 
second line ATT underwent second-line DST by 1% 
proportion  method  using  Lowenstein-Jensen  me-
dia.12 The tested drugs and their critical concentra-
tions were as follows: amikacin (AMK)-30 mcg/mL, 
kanamycin (KAN)-30 mcg/mL, ciprofloxacin (CIP)-
2 mcg/mL, ethionamide (ETM)-40 mcg/mL, cyclo-
serine (CYS)-40 mcg/mL, para-aminosalicylic acid 
(PAS)-1 mcg/mL and clarithromycin (CLA)-2 mcg/
mL (Sigma®, USA).13-14 XDR-TB positive strains by 
1%  proportion  method  were  further  confirmed  by 
line  probe  assays  (GenoType®  MTBDRsl  assay; 
Hain  Lifescience,  Nehren,  Germany)  using  DNA 
probes for mutant genes of fluoroquinolones, ami-
noglycosides and ethambutol.15
HIV serology
After obtaining informed consent from the patients, 
HIV status was determined according to the Joint 
United Nations Programme on HIV/AIDS/WHO rec-
ommendations.16Singh A, K, et al. Trends of extensively drug-resistant tuberculosis 171
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Statistical analysis
Data  was  analyzed  using  SPSS  15.0  (Statistical 
Package for the Social Sciences, Chicago, IL, USA) 
for Windows. Standard χ2 tests were used to as-
sess  statistical  relationships  between  HIV  status 
and XDR-TB. P value of <0.05 was considered sta-
tistically significant.
RESULTS
Among the 430 culture positive Mycobacterium spe-
cies isolated, 365 were identified as MTBC (84.9%) 
both by NAP and TB MPT64 Ag test (100% agree-
ment) and 65 (15.1%) as non-tuberculous mycobac-
teria (NTM), which were excluded from this study 
(Figure 1). Out of these 365 MTBC isolates included 
in this study for first line DST, 156 (42.7%) patients 
were previously taken ATT, 146 (40%) were new 
cases and in 63 (17.3%) cases ATT status was un-
known. Out of these entire 365 patients, 233 (63.8%) 
male, and 132 (36.2%) were female; and their mean 
age and standard deviation were (35.7±14.1) years. 
As per recommendation, HIV was also tested in 300 
subjects (82.2%), in which 55 were positive (18.3%) 
and 245 were negative (83.5%).
Among the 365 MTBC isolates after first line 
DST, 139 (38.1%) MDR-TB, 103 (28.2%) non-MDR-
TB and 123 (33.7%) were pan-susceptible MTBC 
isolates. All non-MDR-TB and pan-susceptible iso-
lates were further excluded from second line DST. 
The association of HIV among MDR-TB and non-
MDR-TB  was  insignificant  (p>0.05).  Only  97/139 
(69.8%) MDR-TB isolates were tested with second 
line drugs, among which 63 (65%) patients were al-
ready on one or multiple second line ATT for more 
than  two  months,  and  34  (35%)  subjects  were 
planned for second line ATT. Prevalence of XDR-
TB was 15/97 (15.5%) by DST using both 1% pro-
portion method and the GenoType® MTBDRsl as-
say (Figure 1; 100% agreement with 1% proportion 
method for second line drugs and ethambutol). A 
continuous increasing trend of XDR-TB was noted 
from 2007 to 2011 at our center (Figure 2). 
Figure  1.  Flow  chart  of 
study  isolates  recruited 
for  XDR-TB  prevalence 
among MDR-TB isolates
Among the 15 XDR-TB subjects, the age range 
was from 22 to 67 years, in which 10 were male 
(66.7%) and 5 were female (33.7%). Out of these 
15 XDR-TB subjects, 11 (73.3%) subjects were hav-
ing history of fever, cough with sputum, and remain-
ing 4 (26.7%) having fever with hemoptysis. Simi-
larly 4 (40%) subjects were HIV sero-positive, and 
6 (60%) were negative, and remaining 5 patients 
were could not be tested. In addition, 10 XDR-TB 
subjects were having history of TB contact, and 5 
subjects did not have history of contact with con-
firmed TB case. Among these total 15 XDR-TB sub-
jects, 6 were already on treatment with second line 
ATT drugs, 5 completed first and second line ATT 
regimens, 2 completed only first line ATT drugs and 
in remaining 2 subjects history of ATT/TB contacts 
were described (Table 1).Singh A, K, et al. Trends of extensively drug-resistant tuberculosis 172
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Table 1. Demographic summary of XDR-TB subjects (n=15)
No Age/Sex Symptoms, signs Previous therapy/
Duration (months)
Year back Contact with
a tuberculosis patient
HIV-status
1 40/M Fever, hemoptysis NO - YES POSITIVE
2 29/F Cough, sputum, fever YES/ (8) 2 NO ND
3 40/M Cough, sputum, fever YES (6) >4 NO NEGATIVE
4 33/M Cough, sputum, fever NO - YES NEGATIVE
5 57/F Cough, sputum, fever YES (6) 4 NO POSITIVE
6  34/M Cough, sputum, fever NO - YES NEGATIVE
7 32/M Cough, sputum, fever YES (18) 2 YES ND
8 29/M Fever, hemoptysis YES (12) 1.5 YES NEGATIVE
9 61/F Cough, sputum, fever NO - YES NEGATIVE
10 23/M Cough, sputum, fever YES (12) 1.5 NO POSITIVE
11 67/M Cough, sputum, fever NO - NO ND
12 41/M Fever, hemoptysis YES (6) 2 YES ND
13 56/M Cough, sputum, fever YES (8) 3 YES POSITIVE
14 22/M Cough, sputum, fever YES (8) 3 YES NEGATIVE
15 35/M Fever, hemoptysis YES (18) 2 YES ND
M: male, F: female, ND: Not determined
Figure  2.  Year  wise 
trends  of  MDR-TB, 
XDR-TB and number 
of isolates over which 
second line DST per-
formed  shows  up-
wards trend (January 
2007  to  December 
2011)Singh A, K, et al. Trends of extensively drug-resistant tuberculosis 173
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The  obtained  resistance  patterns  of  first  line 
drugs in which all 139 (100%) isolates were resis-
tant to H and R (MDR-TB), 80 (57.6%) were resis-
tant to E and 82 (59%) were resistant to S. Resis-
tance to different second line drugs tested among 
XDR-TB  strains  are  shown  in  Table  2;  in  which 
CLA resistance was seen in 13/15 (86.7%) strains. 
The overall resistance pattern of second line drugs 
among MDR-TB; for CIP 52.6%, AMK 17.5%, KAN 
8.3%, CLA 88.7%, ETM 57.6%, CYS 58.8% and 
PAS  15.5%  were  detected  using  1%  proportion 
method. Among the 15 XDR-TB strains, 10 (66.7%) 
were seen with the resistance of HRES group and 
remaining HR, HRE and HRS revealed 5 (33.3%) 
among all these three categories of MDR-TB iso-
lates. Non-XDR-TB having resistance with HR seen 
in 16 (19.5%), HRE in 13 (15.9%), HRS in 7 (8.5%) 
and HRES in 46 (56.1%) out of 82 isolates. The re-
sistant patterns of HRES were higher in both XDR-
TB (66.7%) and non-XDR-TB (56.1%) groups. In 
XDR-TB with second line drugs resistance patterns 
were HR + CIP + AMK in 10 (66.7%) and HR + CIP 
+ AMK + KAN in 5 (33.3%) and among non-XDR-TB 
different resistance patterns are shown in the Table 
3. This could be due to cross resistance between 
AMK and KAN used to treat drug-resistant TB.
Table 2. Resistance patterns of first line and second line 
drugs  among  MDR-TB  and  XDR-TB  and  non-XDR-TB 
isolates*
Drugs MDR-TB
(n=139)
XDR-TB
(n=15)
Non-XDR-TB
(n=82)
First line drugs
Isoniazid 139 (100)
Rifampicin 139 (100)
Ethambutol 80 (57.6)
Streptomycin 82 (59)
Second line drugs
Ciprofloxacin 15 (100) 36 (43.9)
Amikacin 15(100) 12 (14.6)
Kanamycin 5 (33.3) 3 (3.6)
Clarithromycin 13 (86.7) 73 (89.1)
Cycloserine 5 (33.3) 52 (63.4)
Ethionamide 5 (33.3) 18 (21.9)
Para-amino
 salicylic acid 4 (26.7) 11 (14.6)
*Data expressed as n (%)
Table 3. Resistant patterns of second line drugs among XDR-TB and non-XDR-TB isolates
XDR-TB (n=15) Non-XDR-TB (n=82) Total
Pattern HR+CIP+AMK HR+CIP+AMK+KAN HR+MK HR +CIP HR+KAN HR+AMK+KAN HR
XDR-TB 10 (66.7) 5 (33.3) - - - - - 15 (100)
Non-XDR-TB - - 11 (13.4) 37 (45.1) 2 (2.4) 2 (2.4) 30 (36.6) 82 (100)
H=Isoniazid, R=Rifampicin, CIP=Ciprofloxacin, AMK=Amikacin, KAN=Kanamycin, XDR=Extensively drug-resistant
DISCUSSION
The  present  study  has  shown  the  prevalence  of 
XDR-TB 15.4% among MDR-TB at a tertiary care 
center in Lucknow, India. Various studies from In-
dia showed the prevalence of XDR-TB ranging from 
2.4% to 15.3%.17-18 India, China and Russia Fed-
eration carry the greatest burden of XDR-TB, jointly 
contributed for more than half cases of the globe.19 
XDR-TB strains are emerged when either MDR-TB 
is inadequately or incompletely treated or prolong 
inadequate therapy for suspected NTM due to lack 
of differentiation between NTM and MTBC isolates 
especially  in  pulmonary  infection  in  developing 
countries.20
Co-infection of HIV and TB, a well-known en-
tity, increases the mortality in all forms of TB and 
if MDR-TB/XDR-TB arises with HIV then it became 
more difficult to treat. In 2009, it has been report-
ed  that  1.7  million  HIV  positive  individuals  were 
screened  for  TB  in  101  countries.20  A  few  stud-
ies  showed  previously  that  HIV  seroprevalence 
among MDR-TB patients was 4.42% and Singh et 
al. reported 4 tuberculosis cases causing MDR-TB 
(33.3%) among the 12 HIV positive subjects.21,22 In 
the present study, co-infection of HIV and MDR-TB 
were detected in 45 (16.3%) out of 273 subjects and 
co-infection of HIV and XDR-TB were detected in 4 
(40%) out of 10 subjects. So we cannot make any 
conclusion regarding impact of HIV over drug resis-
tance from this limited data especially in XDR-TB 
with HIV. 
A study including large number of cases and 
mycobacterium strains from 13 TB reference labora-
tories showed that no single-drug resistance in 884 
cases (15.4%), poly-resistance other than MDR-TB Singh A, K, et al. Trends of extensively drug-resistant tuberculosis 174
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in 651 cases (11.5%), and MDR-TB in 2.222 cases 
(39.4%) were present respectively.5,20 Present study 
showed that no single-drug resistance was seen in 
256/365 (70.1%) and similarly MDR-TB was seen in 
139/365 (38.1%) cases. In this study resistance to 
ciprofloxacin was detected in 52.6%, clarithromycin 
resistance in 88.7% strains and the reason may be 
inadequately treated NTM infections without proper 
laboratory confirmation or because of non-adherent 
ATT in “highly suspected DR-TB” cases. 
In India, the resistance trends in first line drugs 
and combination with second line drugs were re-
ported previously as HR + CIP + KAN in 63/382 
(16.5%), HR + ETH + CIP + KAN in 7/382 (1.8%), 
HR + ETH + STP + CIP + KAN in 36/382 (9.4%) and 
HR + ETH + STP + CIP + KAN in 276/382 (72.3%) 
in a three year of experience.23 In contrast to that 
study, we observed that the resistance rates against 
HR with second line drugs (HR + CIP + AMK) as 
66.7% and to HR + CIP + AMK + KAN as 33.3% 
among  the  XDR-TB  strains.  The  misuse  of  HR 
might  exacerbated  the  situation  especially  in  de-
veloping countries, which might be explained their 
higher resistance levels especially in MDR-TB and 
XDR-TB as well as non-XDR-TB isolates.24 Fluoro-
quinolones are strongly recommended by WHO for 
treating MDR-TB patients for whom the regular reg-
imens  are  unsustainable.25  Unfortunately,  treating 
MDR-TB with second-line drugs inevitably leads to 
the emergence of further drug resistance like non-
XDR-TB and then XDR-TB strains.
We accept the existence of some limitations in 
our study. First of all, the study is performed at a 
single referral center in India. Although the full ex-
tent of XDR-TB in India and beyond is not very well 
known, growing evidence suggests that cases are 
not confined to a local population cluster. Second, 
due to the TB cases, who enrolled this study being 
clinically “highly suspected DR-TB” the prevalence 
of MDR-TB as well as XDR-TB may be over-pro-
jected and it cannot be extrapolated to the gener-
al population. Third, survivals of all drug resistant 
TB cases were not taken into consideration in this 
study. Despite these limitations, this study provides 
disturbing new evidence of the prevalence, patterns 
and serious impact of XDR-TB in a resource-limited 
area, with a high prevalence of HIV. This highlights 
the need for urgent local and international interven-
tion to reduce the emergence of XDR-TB by improv-
ing the early diagnosis as well as better therapeutic 
measures.
In conclusion, laboratory proven prevalence of 
XDR-TB was 15.4% among MDR-TB cases and it 
is not the XDR-TB status is rising, but non-XDR-TB 
status with pan-resistance is almost equally serious 
and rising and finally converting into the XDR-TB 
strains. The laboratory testing of “highly suspected 
DR-TB” cases should be done for both first and sec-
ond line anti-tubercular drugs to diagnose drug re-
sistance patterns. The added advantage of DST is 
an epidemiological assessment of whether XDR-TB 
increasing in a particular geographical region and 
their different resistance patterns in XDR-TB. 
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